The DOI matches its Crossref record.
Griffithsin Has Antiviral Activity against Hepatitis C Virus
Open accessAbstract
Hepatitis C virus (HCV)-infected patients undergoing liver transplantation universally experience rapid reinfection of their new liver graft. Current treatment protocols do not prevent graft reinfection and, in addition, an accelerated disease progression is observed. In the present study, we have evaluated a novel strategy to prevent HCV infection using a lectin, griffithsin (GRFT) that specifically binds N-linked high-mannose oligosaccharides that are present on the viral envelope. The antiviral effect of GRFT was evaluated in vitro using the HCV pseudoparticle (HCVpp) and HCV cell culture (HCVcc) systems. We show here that preincubation of HCVpp and HCVcc with GRFT prevents infection of Huh-7 hepatoma cells. Furthermore, GRFT interferes with direct cell-to-cell transmission of HCV. GRFT acts at an early phase of the viral life cycle by interfering in a genotype-independent fashion with the interaction between the viral envelope proteins and the viral receptor CD81. The capacity of GRFT to prevent infection in vivo was evaluated using uPA +/+ -SCID mice (uPA stands for urokinase-type plasminogen activator) that harbor human primary hepatocytes in their liver (chimeric mice). In this proof-of-concept trial, we demonstrated that GRFT can mitigate HCV infection of chimeric mice. Treated animals that did become infected demonstrated a considerable delay in the kinetics of the viral infection. Our data demonstrate that GRFT can prevent HCV infection in vitro and mitigate HCV infection in vivo . GRFT treatment of chronically infected HCV patients undergoing liver transplantation may be a suitable strategy to prevent infection of the liver allograft.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
COVID-19: Transmission, prevention, and potential therapeutic opportunities
Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.044 · Cited by 1,016
Antiviral Natural Products and Herbal Medicines
Lin, L.-T., Hsu, W.-C., & Lin, C.-C. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124335 · Cited by 529
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Boldescu, V., Behnam, M. A. M., Vasilakis, N., & Klein, C. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.33 · Cited by 305
Host-Directed Antiviral Therapy
Kumar, N., Sharma, S., Kumar, R., Tripathi, B. N., Barua, S., Ly, H., & Rouse, B. T. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00168-19 · Cited by 271
Lee, C. (2019) · Marine Drugs · doi:10.3390/md17100567 · Cited by 138
Metadata
- Authors
- Meuleman, P., Albecka, A., Belouzard, S., Vercauteren, K., Verhoye, L., Wychowski, C., Leroux-Roels, G., Palmer, K. E., & Dubuisson, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-11
- Volume
- 55
- Issue
- 11
- Pages
- 5159-5167
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2151678945
- Cited by
- 160
- References
- 0
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Griffithsin Has Antiviral Activity against Hepatitis C Virus. https://app.cochat.ai/papers/10.1128/aac.00633-11
- The paper
- Meuleman, P., Albecka, A., Belouzard, S., Vercauteren, K., Verhoye, L., Wychowski, C., Leroux-Roels, G., Palmer, K. E., & Dubuisson, J. (2011). Griffithsin Has Antiviral Activity against Hepatitis C Virus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00633-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.